登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688029 证券简称：南微医学公告编号：2025-049 南微医学科技股份有限公司 持股5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 大股东持股的基本情况 本次减持计划实施前，深圳市中科招商创业投资有限公司（以下简称"中科招商"）持有南微医学科技股 份有限公司（以下简称"公司"）股份41,752,818股，占公司总股本的22.2270%。上述股份来源为公司首 次公开发行股票并上市前取得的股份，及该等股份于公司2022年实施资本公积转增股本时获得股份，上 述股份已于2022年7月22日起上市流通。 ● 减持计划的实施结果情况 2025年8月18日，公司在上海证券交易所网站（www.sse.com.cn）披露了《南微医学科技股份有限公司 持股5%以上股东减持股份计划公告》（公告编号：2025-036），公司股东中科招商拟通过上海证券交 易所交易系统以集中竞价、大宗交易方式减持公司股份合计不超过3,756, ...

Core Viewpoint - The company, Nanwei Medical Technology Co., Ltd., is currently involved in a patent invalidation request initiated by Beijing Zhongke Shengkang Technology Co., Ltd., which may impact its patent rights and potential compensation from a previous infringement lawsuit [1][2]. Group 1: Case Background - The case is at the stage of acceptance and has not yet been reviewed [1]. - The company is the patent holder involved in the dispute [1]. - The patent in question is for a hemostatic clip (Patent No. 201410222753.7), which was applied for on May 23, 2014, and granted on November 18, 2015 [2]. Group 2: Previous Litigation - The company initiated a patent infringement lawsuit against Zhongke Shengkang, which resulted in a ruling that found Zhongke Shengkang guilty of infringement, ordering them to cease infringing activities and pay the company 700,000 yuan [2]. - Zhongke Shengkang has appealed the first-instance judgment to the Supreme People's Court, and the case is still under review [2]. Group 3: Impact on Company - If the patent is ultimately declared invalid, competitors may use the technology without compensation to the company, affecting the potential recovery from the previous lawsuit [1][3]. - The company asserts that the invalidation of the patent will not significantly impact its production and sales, as it has a robust core technology system that includes multiple patents and technical know-how [4]. - The company reported that its domestic sales of products utilizing the disputed patent were approximately 100 million yuan in 2024 [3].